A second endogenous cannabinoid that modulates long-term potentiation
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Cannabinoid receptors are molecular targets for marijuana and hashish, the widespread drugs of abuse. These receptors are expressed in areas of the central nervous system that contribute in important ways to the control of memory, cognition, movement and pain perception. Indeed, such functions can be strongly influenced by cannabinoid drugs, with consequences that include euphoria, analgesia, sedation and memory impairment. Although the pharmacology of cannabinoid drugs is now beginning to be understood, we still lack essential information on the endogenous signalling system(s) by which cannabinoid receptors are normally engaged. An endogenous ligand for cannabinoid receptors, anandamide, has been described. Here we report that sn-2 arachidonylglycerol (2-AG), a cannabinoid ligand isolated from intestinal tissue, is present in brain in amounts 170 times greater than anandamide. 2-AG is produced in hippocampal slices by stimulation of the Schaffer collaterals, an excitatory fibre tract that projects from CA3 to CA1 neurons. Formation of 2-AG is calcium dependent and is mediated by the enzymes phospholipase C and diacylglycerol lipase. 2-AG activates neuronal cannabinoid receptors as a full agonist, and prevents the induction of long-term potentiation at CA3-CA1 synapses. Our results indicate that 2-AG is a second endogenous cannabinoid ligand in the central nervous system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Anandamide and 2-AG are partial and full CB1R agonists, respectively, with the latter being present at much higher concentrations and therefore is the major known contributor to eCB signaling in the brain (1053).”
From Hippocampal GABAergic Inhibitory Interneurons (2017) · cites this paper as [1053]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 3×
“excitatory postsynaptic potentials (EPSPs) (1) before and (2) 60min after HFS of”
Background2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Self-citationEffects of ischemia and electroconvulsive shock on free fatty acid pool in the brain
Bazán, N. G. (1970) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(70)90086-x · Cited by 855
Functional Role of High-Affinity Anandamide Transport, as Revealed by Selective Inhibition
Beltramo, M., Stella, N., Calignano, A., Lin, S. Y., Makriyannis, A., & Piomelli, D. (1997) · Science · doi:10.1126/science.277.5329.1094 · Cited by 813
Self-citationPharmacology of Cannabinoid Receptors
Howlett, A. C. (1995) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.35.040195.003135 · Cited by 488
Cadas, H., di Tomaso, E., & Piomelli, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-04-01226.1997 · Cited by 396
Self-citation
Cited by
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“…is unaffected by pharmacological blockade of FAAH (Kim and Alger, 2004), but it is potentiated by blocking MGL (Kim and Alger, 2004; Makara et al., 2005), in agreement with an earlier study implicating 2-AG rather than anandamide in synaptic plasticity in the hippocampus (Stella et al., 1997).”
ResultThe molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
“These diverse metabolic roles can explain its high concentration in brain tissue (about 200-fold greater than anandamide's”
BackgroundSelf-citationEndogenous cannabinoids mediate retrograde signalling at hippocampal synapses
Wilson, R. I., & Nicoll, R. A. (2001) · Nature · doi:10.1038/35069076 · Cited by 1,607
“Two endogenous lipids, anandamide and 2-arachidonylglycerol (2-AG), have been identified as CB1 ligand”
Role of Endogenous Cannabinoids in Synaptic Signaling
FREUND, T. F., KATONA, I., & PIOMELLI, D. (2003) · Physiological Reviews · doi:10.1152/physrev.00004.2003 · Cited by 1,574
Self-citationEndocannabinoid-Mediated Control of Synaptic Transmission
Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,529
Brain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373
Self-citationModulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
Self-citationEndocannabinoid Signaling in the Brain
Wilson, R. I., & Nicoll, R. A. (2002) · Science · doi:10.1126/science.1063545 · Cited by 1,260
Katona, I., Sperlágh, B., Sı́k, A., Käfalvi, A., Vizi, E. S., Mackie, K., & Freund, T. F. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-11-04544.1999 · Cited by 1,218
“Two potential endogenous substrates, anandamide (Devane et al., 1992) and sn-2 arachidonylglycerol (Stella et al., 1997), have also been characterized.”
BackgroundThe endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Control of pain initiation by endogenous cannabinoids
Calignano, A., Rana, G. L., Giuffrida, A., & Piomelli, D. (1998) · Nature · doi:10.1038/28393 · Cited by 1,056
Self-citationBisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M. G., Ligresti, A., Matias, I., Schiano-Moriello, A., Paul, P., Williams, E.-J., et al. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200305129 · Cited by 1,039
“Both enzymes are equally sensitive to Ser/Cyshydrolase inhibitors such as p -hydroxy-mercuri-benzoate and HgCl 2 , but not to PMSF. Importantly, both enzymes are inhibited by RHC80267, a drug that blocks 2-AG formation from intact cells (Bisogno et al., 1997; Stella et al., 1997).”
BackgroundInfluentialHippocampal GABAergic Inhibitory Interneurons
Pelkey, K. A., Chittajallu, R., Craig, M. T., Tricoire, L., Wester, J. C., & McBain, C. J. (2017) · Physiological Reviews · doi:10.1152/physrev.00007.2017 · Cited by 889
Marsicano, G., & Lutz, B. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00847.x · Cited by 937
Kreitzer, A. C., & Regehr, W. G. (2001) · Neuron · doi:10.1016/s0896-6273(01)00246-x · Cited by 875
Ohno-Shosaku, T., Maejima, T., & Kano, M. (2001) · Neuron · doi:10.1016/s0896-6273(01)00247-1 · Cited by 845
The effects of cannabinoids on the brain
Ameri, A. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00087-2 · Cited by 812
ENDOCANNABINOID-MEDIATED SYNAPTIC PLASTICITY IN THE CNS
Chevaleyre, V., Takahashi, K. A., & Castillo, P. E. (2006) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.29.051605.112834 · Cited by 783
An endocannabinoid mechanism for stress-induced analgesia
Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fegley, D., Mangieri, R., Krey, J. F., Michael Walker, J., Holmes, P. V., Crystal, J. D., et al. (2005) · Nature · doi:10.1038/nature03658 · Cited by 778
Self-citationDopamine activation of endogenous cannabinoid signaling in dorsal striatum
Giuffrida, A., Parsons, L. H., Kerr, T. M., de Fonseca, F. R., Navarro, M., & Piomelli, D. (1999) · Nature Neuroscience · doi:10.1038/7268 · Cited by 775
Self-citationPostsynaptic endocannabinoid release is critical to long-term depression in the striatum
Gerdeman, G. L., Ronesi, J., & Lovinger, D. M. (2002) · Nature Neuroscience · doi:10.1038/nn832 · Cited by 767
Iversen, L. (2003) · Brain · doi:10.1093/brain/awg143 · Cited by 732
Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action
Di Marzo, V., Melck, D., Bisogno, T., & De Petrocellis, L. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01283-1 · Cited by 712
Cannabinoids: potential anticancer agents
Guzmán, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1188 · Cited by 703
Galve-Roperh, I., Sánchez, C., Cortés, M. L., del Pulgar, T. G., Izquierdo, M., & Guzmán, M. (2000) · Nature Medicine · doi:10.1038/73171 · Cited by 682
Nonpsychotropic Cannabinoid Receptors Regulate Microglial Cell Migration
Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., Mackie, K., & Stella, N. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-04-01398.2003 · Cited by 665
Self-citationHeterosynaptic LTD of Hippocampal GABAergic Synapses
Chevaleyre, V., & Castillo, P. E. (2003) · Neuron · doi:10.1016/s0896-6273(03)00235-6 · Cited by 655
Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens
Robbe, D., Kopf, M., Remaury, A., Bockaert, J., & Manzoni, O. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122149199 · Cited by 631
Multiple Functions of Endocannabinoid Signaling in the Brain
Katona, I., & Freund, T. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062111-150420 · Cited by 630
“The canonical pathway includes phospholipase Cβs, which hydrolyze phophatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5triphosphate (IP3) and DAG (Stella et al., 1997).”
BackgroundBen-Shabat, S., Fride, E., Sheskin, T., Tamiri, T., Rhee, M.-H., Vogel, Z., Bisogno, T., De Petrocellis, L., Di Marzo, V., & Mechoulam, R. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00392-6 · Cited by 629
Cannabinoid physiology and pharmacology: 30 years of progress
Howlett, A. C., Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., & Porrino, L. J. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.030 · Cited by 608
“This has become more significant now that at least two endocannabinoids, anandamide and 2-arachidonoylglycerol (2AG), have been isolated from brain extracts (Devane et al., 1992; Mechoulam et al., 1995; Cadas et al., 1996; Stella et al., 1997; Sugiura et al., 1995).”
BackgroundRetrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids
E. Alger, B. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00080-1 · Cited by 598
Endocannabinoid signaling as a synaptic circuit breaker in neurological disease
Katona, I., & Freund, T. F. (2008) · Nature Medicine · doi:10.1038/nm.f.1869 · Cited by 579
Gulyas, A. I., Cravatt, B. F., Bracey, M. H., Dinh, T. P., Piomelli, D., Boscia, F., & Freund, T. F. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03428.x · Cited by 561
“, 1997), while phospholipase C and diacylglycerol lipase are thought to be involved in the synthesis of 2-AG (Stella et al., 1997).”
BackgroundSelf-citationCannabinoid receptors and their ligands
Pertwee, R. G., & Ross, R. A. (2002) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1054/plef.2001.0341 · Cited by 561
Farooqui, A. A., Horrocks, L. A., & Farooqui, T. (2000) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(00)00128-6 · Cited by 555
Maejima, T., Hashimoto, K., Yoshida, T., Aiba, A., & Kano, M. (2001) · Neuron · doi:10.1016/s0896-6273(01)00375-0 · Cited by 555
Howlett, A. C. (2002) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(02)00060-6 · Cited by 535
Cannabis use and cannabis use disorder
Connor, J. P., Stjepanović, D., Le Foll, B., Hoch, E., Budney, A. J., & Hall, W. D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00247-4 · Cited by 552
The acute effects of cannabinoids on memory in humans: a review
Ranganathan, M., & D’Souza, D. C. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0508-y · Cited by 525
Ligands for Glutamate Receptors: Design and Therapeutic Prospects
Bräuner-Osborne, H., Egebjerg, J., Nielsen, E. Ø., Madsen, U., & Krogsgaard-Larsen, P. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000007r · Cited by 524
Molecular Composition of the Endocannabinoid System at Glutamatergic Synapses
Katona, I., Urbán, G. M., Wallace, M., Ledent, C., Jung, K.-M., Piomelli, D., Mackie, K., & Freund, T. F. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0309-06.2006 · Cited by 511
Self-citationInvolvement of CB1 cannabinoid receptors in emotional behaviour
Martin, M., Ledent, C., Parmentier, M., Maldonado, R., & Valverde, O. (2002) · Psychopharmacology · doi:10.1007/s00213-001-0946-5 · Cited by 507
CANNABINOID RECEPTORS AS THERAPEUTIC TARGETS
Mackie, K. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141254 · Cited by 505
Review of the Endocannabinoid System
Lu, H.-C., & Mackie, K. (2021) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2020.07.016 · Cited by 491
Endocannabinoid Signaling and Long-Term Synaptic Plasticity
Heifets, B. D., & Castillo, P. E. (2009) · Annual Review of Physiology · doi:10.1146/annurev.physiol.010908.163149 · Cited by 482
Melis, M., Pistis, M., Perra, S., Muntoni, A. L., Pillolla, G., & Gessa, G. L. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4503-03.2004 · Cited by 478
The Endocannabinoid System and Pain
Guindon, J., & Hohmann, A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824660 · Cited by 476
The endocannabinoid system: a general view and latest additions
Petrocellis, L. D., Cascio, M. G., & Marzo, V. D. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705666 · Cited by 475
Cannabinoids and Neuroprotection in Global and Focal Cerebral Ischemia and in Neuronal Cultures
Nagayama, T., Sinor, A. D., Simon, R. P., Chen, J., Graham, S. H., Jin, K., & Greenberg, D. A. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-08-02987.1999 · Cited by 468
Phillis, J. W., Horrocks, L. A., & Farooqui, A. A. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.02.002 · Cited by 459
Pharmacological Profile of the Selective FAAH Inhibitor KDS-4103 (URB597)
Piomelli, D., Tarzia, G., Duranti, A., Tontini, A., Mor, M., Compton, T. R., Dasse, O., Monaghan, E. P., Parrott, J. A., & Putman, D. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00021.x · Cited by 441
Self-citationThe serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors
Marrs, W. R., Blankman, J. L., Horne, E. A., Thomazeau, A., Lin, Y. H., Coy, J., Bodor, A. L., Muccioli, G. G., Hu, S. S.-J., Woodruff, G., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2601 · Cited by 441
Self-citationElevated endogenous cannabinoids in schizophrenia
Leweke, F. M., Giuffrida, A., Wurster, U., Emrich, H. M., & Piomelli, D. (1999) · NeuroReport · doi:10.1097/00001756-199906030-00008 · Cited by 432
Self-citationMechoulam, R., Fride, E., & Di Marzo, V. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00649-9 · Cited by 428
Fegley, D., Gaetani, S., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.078980 · Cited by 427
Self-citationThe Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease
Long, J. Z., & Cravatt, B. F. (2011) · Chemical Reviews · doi:10.1021/cr200075y · Cited by 425
The endocannabinoid system as a target for therapeutic drugs
Piomelli, D., Giuffrida, A., Calignano, A., & Rodrı́guez de Fonseca, F. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01482-6 · Cited by 421
“Selected references a Stella, N. et al. (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773–778 b Shen, M. et al. (1996) Cannabinoid receptor agonists inhibit glutamatergic c synaptic transmission in rat hippocampal cultures. J. Neurosci. 16, 4322–4334 c Szabo, B. et al. (1998…”
BackgroundInfluentialSelf-citationHájos, N., Ledent, C., & Freund, T. F. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00287-1 · Cited by 419
The neurobiology and evolution of cannabinoid signalling
Elphick, M. R., & Egertova, M. (2001) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.2000.0787 · Cited by 417
An analgesia circuit activated by cannabinoids
Meng, I. D., Manning, B. H., Martin, W. J., & Fields, H. L. (1998) · Nature · doi:10.1038/26481 · Cited by 411
Dietrich, A., & McDaniel, W. F. (2004) · British Journal of Sports Medicine · doi:10.1136/bjsm.2004.011718 · Cited by 410
Varga, K., Wagner, J. A., Bridgen, D. T., & Kunos, G. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.11.1035 · Cited by 410
THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY
RODRÍGUEZ de FONSECA, F., DEL ARCO, I., BERMUDEZ-SILVA, F. J., BILBAO, A., CIPPITELLI, A., & NAVARRO, M. (2005) · Alcohol and Alcoholism · doi:10.1093/alcalc/agh110 · Cited by 407
Metabotropic Glutamate Receptors Drive the Endocannabinoid System in Hippocampus
Varma, N., Carlson, G. C., Ledent, C., & Alger, B. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-24-j0003.2001 · Cited by 406
From drugs to deprivation: A Bayesian framework for understanding models of psychosis
Corlett, P. R., Frith, C. D., & Fletcher, P. C. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1561-0 · Cited by 367
“1992), second messenger systems (Stella et al. 1997) and cannabinoid receptor antagonists (Rinaldi-Carmona et al.”
BackgroundWallace, M. J., Blair, R. E., Falenski, K. W., Martin, B. R., & DeLorenzo, R. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051920 · Cited by 393
Kozak, K. R., Rowlinson, S. W., & Marnett, L. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m007088200 · Cited by 390
CANNABINOID RECEPTORS AND THEIR ENDOGENOUS AGONISTS
Felder, C. C., & Glass, M. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.179 · Cited by 390
Evidence for novel cannabinoid receptors
BEGG, M., PACHER, P., BATKAI, S., OSEIHYIAMAN, D., OFFERTALER, L., MO, F., LIU, J., & KUNOS, G. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.11.005 · Cited by 385
Functional interaction between opioid and cannabinoid receptors in drug self-administration.
Navarro, M., Carrera, M. R. A., Fratta, W., Valverde, O., Cossu, G., Fattore, L., Chowen, J. A., Gómez, R., del Arco, I., Villanúa, M. A., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-14-05344.2001 · Cited by 378
“It is composed by the cannabinoid CB1 receptor (Devane et al., 1988; Matsuda et al., 1993), several endogenous lipid transmitters, including anandamide (Devane et al., 1992) and 2-archidonyl glycerol (Mechoulam et al., 1995; Stella et al., 1997 ).”
BackgroundUchigashima, M., Narushima, M., Fukaya, M., Katona, I., Kano, M., & Watanabe, M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0448-07.2007 · Cited by 375
Sugiura, T., Kondo, S., Kishimoto, S., Miyashita, T., Nakane, S., Kodaka, T., Suhara, Y., Takayama, H., & Waku, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.605 · Cited by 371
Di Marzo, V. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.02.010 · Cited by 368
Rodrı́guez, J. J., Mackie, K., & Pickel, V. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-03-00823.2001 · Cited by 363
Hill, M. N., Patel, S., Carrier, E. J., Rademacher, D. J., Ormerod, B. K., Hillard, C. J., & Gorzalka, B. B. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300601 · Cited by 363
“…in other neurotransmitter systems could be mediating the changes in eCB levels; however, due to the fact that stress stimulates excitatory transmission in the hippocampus (McEwen and Magarinos, 1997), one would actually expect an increase and not a decrease in eCB levels (Stella et al, 1997).”
BackgroundSUGIURA, T., KISHIMOTO, S., OKA, S., & GOKOH, M. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.03.003 · Cited by 352
The Endocannabinoid System: Drug Targets, Lead Compounds, and Potential Therapeutic Applications
Lambert, D. M., & Fowler, C. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058183t · Cited by 350
Sugiura, T., Kobayashi, Y., Oka, S., & Waku, K. (2002) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1054/plef.2001.0356 · Cited by 348
Bortolato, M., Mangieri, R. A., Fu, J., Kim, J. H., Arguello, O., Duranti, A., Tontini, A., Mor, M., Tarzia, G., & Piomelli, D. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.001 · Cited by 347
Self-citationCannabinoids and neuroinflammation
Walter, L., & Stella, N. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705667 · Cited by 336
Self-citationCarrier, E. J., Kearn, C. S., Barkmeier, A. J., Breese, N. M., Yang, W., Nithipatikom, K., Pfister, S. L., Campbell, W. B., & Hillard, C. J. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.4.999 · Cited by 336
Egertová, M., Giang, D. K., Cravatt, B. F., & Elphick, M. R. (1998) · Proceedings of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rspb.1998.0543 · Cited by 334
Bossong, M. G., & Niesink, R. J. M. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.010 · Cited by 333
Regulation of Extracellular Signal-Regulated Kinase by Cannabinoids in Hippocampus
Derkinderen, P., Valjent, E., Toutant, M., Corvol, J.-C., Enslen, H., Ledent, C., Trzaskos, J., Caboche, J., & Girault, J.-A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-06-02371.2003 · Cited by 331
Can molecules explain long-term potentiation?
Sanes, J. R., & Lichtman, J. W. (1999) · Nature Neuroscience · doi:10.1038/10154 · Cited by 331
Anandamide amidohydrolase reacting with 2‐arachidonoylglycerol, another cannabinoid receptor ligand
Goparaju, S. K., Ueda, N., Yamaguchi, H., & Yamamoto, S. (1998) · FEBS Letters · doi:10.1016/s0014-5793(97)01603-7 · Cited by 328
Yoshida, T., Fukaya, M., Uchigashima, M., Miura, E., Kamiya, H., Kano, M., & Watanabe, M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0054-06.2006 · Cited by 327
The endocannabinoid system drives neural progenitor proliferation
Aguado, T., Monory, K., Palazuelos, J., Stella‡, N., Cravatt, B., Lutz, B., Marsicano, G., Kokaia, Z., Guzmán, M., & Galve‐Roperh, I. (2005) · The FASEB Journal · doi:10.1096/fj.05-3995fje · Cited by 327
Self-citationA role for monoglyceride lipase in 2-arachidonoylglycerol inactivation
Dinh, T. P., Freund, T. F., & Piomelli, D. (2002) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(02)00150-0 · Cited by 320
Self-citationEndogenous cannabinoid system as a modulator of food intake
Cota, D., Marsicano, G., Lutz, B., Vicennati, V, Stalla, G. K., Pasquali, R., & Pagotto, U. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802250 · Cited by 315
Hashimotodani, Y., Ohno-Shosaku, T., Tsubokawa, H., Ogata, H., Emoto, K., Maejima, T., Araishi, K., Shin, H.-S., & Kano, M. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.004 · Cited by 315
Exercise activates the endocannabinoid system
Sparling, P. B., Giuffrida, A., Piomelli, D., Rosskopf, L., & Dietrich, A. (2003) · Neuroreport · doi:10.1097/00001756-200312020-00015 · Cited by 313
Self-citationDi Marzo, V. (1998) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/s0005-2760(98)00042-3 · Cited by 312
Bisogno, T., Berrendero, F., Ambrosino, G., Cebeira, M., Ramos, J. A., Fernandez-Ruiz, J. J., & Di Marzo, V. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0254 · Cited by 312
Endocannabinoids: synthesis and degradation
Di Marzo, V. (2006) · Reviews of Physiology, Biochemistry and Pharmacology · doi:10.1007/112_0505 · Cited by 311
Evidence That the Cannabinoid CB1 Receptor Is a 2-Arachidonoylglycerol Receptor
Sugiura, T., Kodaka, T., Nakane, S., Miyashita, T., Kondo, S., Suhara, Y., Takayama, H., Waku, K., Seki, C., Baba, N., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.5.2794 · Cited by 310
Long-lasting self-inhibition of neocortical interneurons mediated by endocannabinoids
Bacci, A., Huguenard, J. R., & Prince, D. A. (2004) · Nature · doi:10.1038/nature02913 · Cited by 306
di Marzo, V., Hill, M. P., Bisogno, T., Crossman, A. R., & Brotchie, J. M. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.10.1432 · Cited by 303
Metadata
- Authors
- Stella, N., Schweitzer, P., & Piomelli, D.
- Affiliations
- Neurosciences Institute (US)
- Scripps Research Institute (US)
- Corresponding author
- Piomelli, Daniele
- Venue
- Nature
- Published
- 1997-08-21
- Volume
- 388
- Issue
- 6644
- Pages
- 773-778
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1591647183
- Cited by
- 1,496
- References
- 31
- Citations by year
- 2026: 16 · 2025: 23 · 2024: 34 · 2023: 38 · 2022: 41 · 2021: 59 · 2020: 44 · 2019: 36 · 2018: 36 · 2017: 41 · 2016: 41 · 2015: 56 · 2014: 51 · 2013: 35 · 2012: 64
- FWCI
- 47.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Howard Hughes Medical Institute
- McKnight Foundation
- National Alliance for Research on Schizophrenia and Depression
- National Institutes of Health
- National Institute of General Medical Sciences
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- 2-arachidonoylglycerol, endocannabinoid system, cannabinoid receptors, long-term potentiation, hippocampus, Schaffer collaterals, CA3-CA1 synapses, anandamide, phospholipase C, diacylglycerol lipase
- MeSH terms
- Animals, Arachidonic Acids, Astrocytes, Brain, Brain Chemistry, Calcium, Cannabinoids, Cells, Cultured, Diglycerides, Electric Stimulation, Glycerides, Hippocampus, Ligands, Gas Chromatography-Mass Spectrometry, Neurons, Receptors, Drug, Long-Term Potentiation, Receptors, Cannabinoid, Rats, Polyunsaturated Alkamides, Endocannabinoids, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.